Prevention of cardiovascular disease in patients with rheumatic diseases

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 4, 2006, Pages 741-756

  Domsic, Robyn ^a   Maksimowicz McKinnon, Kathleen ^a   Manzi, Susan ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

atherosclerosis; autoimmune disease; cardiovascular disease; myocardial infarction; rheumatic disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; GLUCOCORTICOID; HOMOCYSTEINE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRAVASTATIN; PREDNISONE; PYRIDOXINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BODY WEIGHT DISORDER; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ACTIVITY; DISEASE CONTROL; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; EXERCISE; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMOBILIZATION; INSULIN RESISTANCE; LIVER DISEASE; LOW FAT DIET; MEDITERRANEAN DIET; MORTALITY; MYOPATHY; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT COUNSELING; PATIENT MONITORING; PHYSICAL DISABILITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; SODIUM RESTRICTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UNITED STATES; WEIGHT GAIN; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; HUMANS; RHEUMATIC DISEASES; RISK ASSESSMENT; RISK FACTORS;

EID: 33748472870     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.04.005     Document Type: Review

References (93)

1. Turesson C., O'Fallon W., Crowson C., et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community-based cohort of patients with rheumatoid arthritis. The Journal of Rheumatology 29 (2002) 62-67
2. Gabriel S., Crowson C., Maradit-Kremers H., et al. Survival in rheumatoid arthritis. A population-based analysis of trends over 40 years. Arthritis and Rheumatism 48 (2003) 54-58
3. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis and Rheumatism 37 (1994) 481-494
4. Maradit-Kremers H., Nicola P., Crowson C., et al. Cardiovascular death in rheumatoid arthritis. A population-based study. Arthritis and Rheumatism 52 (2005) 722-732
5. Navarro-Cano G., del Rincon I., Pogosian S., et al. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis and Rheumatism 48 (2003) 2425-2433
6. del Rincon I., Williams K., Stern M., et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis and Rheumatism 44 (2001) 2737-2745
7. Bulkley B.H., and Roberts W.C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. The American Journal of Medicine 58 (1975) 243-264
8. Urowitz M.B., Bookman A.A., Koehler B.E., et al. The bimodal mortality pattern of systemic lupus erythematosus. The American Journal of Medicine 60 (1976) 221-225
9. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. American Journal of Epidemiology 145 (1997) 408-415
10. Esdaile J.M., Abrahamowicz M., Grodziecky T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis and Rheumatism 44 (2001) 2331-2337
11. de Leeuw K., Sanders J.S., Stegeman C., et al. Accelerated atherosclerosis in Wegener's granulomatosis. Annals of the Rheumatic Diseases 64 (2005) 753-759
12. Vaudo G., Bocci E.B., Shoenfeld Y., et al. Precocious intima-media thickening in patients with primary Sjogren's syndrome. Arthritis and Rheumatism 52 (2005) 3890-3897
13. Ozdemir R., Barutcu I., Sezgin A.T., et al. Vascular endothelial function and plasma homocysteine levels in Behcet's disease. The American Journal of Cardiology 94 (2004) 522-525
14. Vaudo G., Marchesi S., Gerli R., et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Annals of the Rheumatic Diseases 63 (2004) 31-35
15. El-Magadmi M., Bodill H., Ahmad Y., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 110 (2004) 399-404
16. Booth A.D., Jayne D.R.W., Kharbanda R.K., et al. Infliximab improves endothelial dysfunction in systemic vasculitis. A model of vascular inflammation. Circulation 109 (2004) 1718-1723
17. Roman M., Shanker B., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. The New England Journal of Medicine 349 (2003) 2399-2406
18. Manzi S., Selzer F., Sutton Tyrrell K., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis and Rheumatism 42 (1999) 51-60
19. Dessein P.H., Joffe B.I., and Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors, and atherosclerosis in rheumatoid arthritis. Arthritis Research & Therapy 7 (2005) R634-R643
20. Maksimowicz-McKinnon K., and Wilke W.S. Cardiovascular disease in rheumatoid arthritis: adding insult to injury. New Developments in Rheumatic Diseases 3 (2005) 13-18
21. Choi H.K., Hernan M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 (2002) 1173-1177
22. Wallberg-Jonsson S., Ohman M., and Rantapaa-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis?. Scandinavian Journal of Rheumatology 33 (2004) 373-379
23. Popa C., Netea M.G., Radstake T., et al. Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases 64 (2005) 303-305
24. Hurlimann D., Forster A., Noll G., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106 (2002) 2184-2187
25. Jacobsson L.T., Turesson C., Gulfe A., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. The Journal of Rheumatology 32 (2005) 1253-1258
26. Wei L., MacDonald T., and Walker B. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Annals of Internal Medicine 141 (2004) 764-770
27. del Rincon I., O'Leary D., Haas R., et al. Effects of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis and Rheumatism 50 (2004) 3813-3822
28. Zonaca-Nacach A., Barr S., Magder L., et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis and Rheumatism 43 (2000) 1801-1808
29. Bruce I.N., Gladman D.D., and Urowitz M.B. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study. Clinical and Experimental Rheumatology 16 (1998) 435-440
30. Al-Herz A., Ensworth S., Shojania K., and Esdaile J.M. Cardiovascular risk factor screening in systemic lupus erythematosus. The Journal of Rheumatology 30 (2003) 493-496
31. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
32. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894 (2000), World Health Organization, Geneva
33. Costenbander K.H., Wright E., Liang M.H., et al. Cardiac risk factor awareness and management in patients with systemic lupus erythematosus. Arthritis and Rheumatism 51 (2004) 983-988
34. Sköldstam L., Hagfors L., and Johansson G. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 62 (2003) 208-214
35. deLorgeril M., Salen P., Martin J.L., et al. Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon diet heart study. Circulation 99 (1999) 779-785
36. deJong Z., Munneke M., Lems W.F., et al. Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized controlled trial. Arthritis and Rheumatism 50 (2004) 1066-1076
37. Keyser R.E., Rus V., Cade W.T., et al. Evidence for aerobic insufficiency in women with systemic lupus erythematosus. Arthritis and Rheumatism 49 (2003) 16-22
38. Tench C., Bentley D., Vleck F., et al. Aerobic fitness, fatigue and physical disability in systemic lupus erythematosus. The Journal of Rheumatology 29 (2002) 474-481
39. Hall J., Grant J., Blake D., et al. Cardiorespiratory responses to aquatic treadmill walking in patients with rheumatoid arthritis. Physiotherapy Research International 9 (2004) 59
40. Stenstrom C.H., and Minor M.A. Evidence for the benefit of aerobic and strengthening exercise in rheumatoid arthritis. Arthritis and Rheumatism 49 (2003) 428-434
41. Hakkinen A., Sokka T., Kotaniemi A., and Hannonen P. A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis and Rheumatism 44 (2001) 515-522
42. Munneke M., DeJong Z., Zwinderman A.H., et al. Effect of a high-intensity weight-bearing exercise program on radiologic damage progression of the large joints in subgroups of patients with rheumatoid arthritis. Arthritis and Rheumatism 53 (2005) 410-417
43. American Geriatrics Society Panel on Exercise and Osteoarthritis. Exercise prescription for older adults with osteoarthritis pain: consensus practice recommendations. A supplement to the AGS clinical practice guidelines on the management of chronic pain in older adults. Journal of the American Geriatrics Society 49 (2001) 808-823
44. Park Y., Lee S., Suh C., et al. Lipid profile in untreated patients with rheumatoid arthritis. The Journal of Rheumatology 26 (1999) 1701-1704
45. Park Y., Choi H., Kim M., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. The American Journal of Medicine 113 (2002) 188-193
46. Pearson T.A., Blair S.N., Daniels S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (2002) 388-391
47. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
48. Ridker P., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. The New England Journal of Medicine 352 (2005) 20-28
49. Hermann F., Forster A., Chenevard R., et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. Journal of the American College of Cardiology 45 (2005) 461-464
50. VanDoornum S., McColl G., and Wicks I.P. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 63 (2004) 1571-1575
51. McCarey D.W., McInnes I.B., Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 363 (2004) 2015-2021
52. Elliott JR & Vogt M. Underrecognition of cardiovascular risk factors in patients with systemic lupus erythematosus. Circulation; in press (abstract).
53. Kiana A., and Petri M. Predictors of statin toxicity in the lupus atherosclerosis prevention study. Arthritis and Rheumatism 50S (2004) S406
54. Costenbander K.H., Huang J., Kwon H., et al. Pravastatin for hyperlipidemia in systemic lupus erythematosus: a pilot study. Arthritis and Rheumatism 50S (2004) S405-S406
55. Rahman P., Gladman D.D., Urowitz M., et al. The cholesterol lowering effects of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. The Journal of Rheumatology 26 (1999) 325-330
56. Wallace D.J., Metzger A.L., Stecher V.J., et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. The American Journal of Medicine 89 (1990) 322-326
57. Petri M., Lakatta C., Magder L., et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. The American Journal of Medicine 96 (1994) 254-256
58. Murno R., Morrison E., McDonald A.G., et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 56 (1997) 374-377
59. Wallace D.J. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?. Arthritis and Rheumatism 30 (1987) 1435-1436
60. Lockshin M., Tenedios F., Petri M., et al. Cardiac disease in the APS: recommendations for treatment. Committee Consensus Report. Lupus 12 (2003) 518-523
61. Quatraro A., Consoli G., Magno M., et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?. Annals of Internal Medicine 112 (1990) 678-681
62. Gerstein H.C., Thorpe K.E., Taylor D.W., et al. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas - a randomized trial. Diabetes Research and Clinical Practice 55 (2000) 209-219
63. Solomon D.H., Karlson E.W., Rimm E.B., et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis and Rheumatism 50 (2004) 3444-3449
64. Petri M., Perez-Gutthann S., Spence D., and Hochberg M. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. The American Journal of Medicine 93 (1992) 5113-5119
65. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 289 (2003) 2560-2572
66. Lerner D.J., and Kannel W.B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. American Heart Journal 111 (1986) 383
67. Rutter M.K., Meigs J.B., Sullivan L.M., et al. Insulin resistance, the metabolic syndrome and incident cardiovascular events in the Framingham Offspring Study. Diabetes 54 (2005) 3252-3257
68. Posadas-Romero C., Torres-Tamayo M., Zamora-Gonzalez J., et al. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis and Rheumatism 50 (2004) 160-165
69. Paolisso G., Valentini G., Marrazzo G., et al. Evidence for peripheral impaired glucose handling in patients with connective tissues diseases. Metabolism 40 (1991) 902-907
70. Dessein P., Stanwix A., and Joffe B. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Research 4 (2002) R5
71. Genuth S., Alberti K.G., Bennett P., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160
72. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
73. Silfen M.E., Manibo A.M., MCMahon D.J., et al. Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ration may be a simple and useful measure. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 2863-2868
74. Duncan M.H., Singh B.M., Wise P.H., et al. A simple measure of insulin resistance. Lancet 346 (1995) 120-121
75. Hanley A.J., Stern M.P., Williams K., et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease. Diabetes Care 25 (2002) 1177-1183
76. Sekiguchi M., Kurabayashi M., Adachi H., et al. Usefulness of insulin resistance measured by homeostasis model assessment in predicting restenosis after coronary stent placement in nondiabetic patients. The American Journal of Cardiology 93 (2004) 920-922
77. Ridker P., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine 336 (1997) 973-979
78. Ridker P.M., Cushman M., Stampfer M.J., et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97 (1998) 425-428
79. Ridker P.M. Evaluating novel cardiovascular risk factors: can we better predict heart attacks?. Annals of Internal Medicine 130 (1999) 933-937
80. Wong G.C., Morrow D.A., Murphy S., et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy - Thrombolysis in Myocardial Infarction. Circulation 106 (2002) 202
81. Burke A.P., Tracy R.P., Kolodgie F., et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 105 (2002) 2019-2023
82. Lentz S.R. Mechanisms of homocysteine-induced atherothrombosis. Journal of Thrombosis and Haemostasis 3 (2005) 1646-1654
83. Petri M., Roubenoff R., Dallal G.E., et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348 (1996) 1120-1124
84. Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Seminars in Vascular Surgery 5 (2005) 215-221
85. Sanmuganathan P.S., Ghahramani P., Jackson P.R., et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 85 (2001) 265-271
86. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351 (1998) 1755-1762
87. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 357 (2001) 89-95
88. Augustovski F.A., Cantor S.B., Thach C., et al. Aspirin for primary prevention of cardiovascular events. Journal of General Internal Medicine 13 (1998) 824-835
89. Scottish Intercollegiate Guideline Network. Antithrombotic Therapy. A National Clinical Guideline (1999), Scottish Intercollegiate Guideline Network, Edinburgh
90. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 351 (1998) 233-241
91. Rodondi N., and Bauer C.D. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. The American Journal of Medicine 117 (2004) 528-530
92. Hayden M., Pignone J., Phillips C., et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine 136 (2002) 161-172
93. Krishnan E., Lingala V.B., and Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 110 (2004) 1774-1779